✦ LIBER ✦

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

✍ Scribed by Donato A. Di Monte; Alison McCormack; Giselle Petzinger; Ann Marie Janson; Maryka Quik; William J. Langston

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 69 KB
Volume: 15
Category: Article
ISSN: 0885-3185
DOI: 10.1002/1531-8257(200005)15:3<459::aid-mds1006>3.0.co;2-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stimulation of cannabinoid receptors red

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

✍ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

The α2-adrenergic receptor antagonist id

The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

✍ Brian Henry; Susan H. Fox; David Peggs; Alan R. Crossman; Jonathan M. Brotchie 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

Fipamezole (JP-1730) is a potent α2 adre

Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti